NCT01283542 - Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 26, 2012

Primary Completion Date

September 12, 2017

Study Completion Date

September 12, 2017

Conditions

Non-functioning Pituitary Adenoma

Interventions

DRUG

Pasireotide LAR

20 and 40 mg of powder in vials and 2 mL of vehicle in ampoules (for reconstitution) administered as a depot intragluteal IM (intramuscular) injection

Trial Locations (7)

89201260

Novartis Investigative Site, Joinville

04636-000

Novartis Investigative Site, Fortaleza

80030-110

Novartis Investigative Site, Curitiba

21941-913

Novartis Investigative Site, Rio de Janeiro

18618-970

Novartis Investigative Site, Botucatu

04023-900

Novartis Investigative Site, São Paulo

05403 000

Novartis Investigative Site, São Paulo